|
|
||||||||
Focus on Molecular Imaging |
University of California San Francisco
San Francisco, California
Correspondence: For correspondence or reprints contact: John Kurhanewicz, PhD, UCSF Mission Bay Campus, Byers Hall, Room 203E, 1700 4th St., San Francisco, CA 94158-2330. E-mail: John.Kurhanewicz{at}radiology.ucsf.edu
ABSTRACT
In this article, the current and potential clinical roles of 13C magnetic resonance spectroscopy (MRS) and 13C magnetic resonance spectroscopic imaging are presented, with a focus on applications to prostate cancer and hyperpolarized 13C spectroscopic imaging. The advantages of 13C MRS have been its chemical specificity and lack of background signal, with the major disadvantage being its inherently low sensitivity and the subsequent inability to acquire data at a high-enough spatial and temporal resolution to be routinely applicable in the clinic. The approaches to improving the sensitivity of 13C spectroscopy have been to perform proton decoupling and to use endogenous 13C-labeled or enhanced metabolic substrates. With these nominal increases in signal-to-noise ratio, 13C MRS using labeled metabolic substrates has shown diagnostic promise in patients and has been approved by the Food and Drug Administration. The development of technology that applies dynamic nuclear polarization to generate hyperpolarized 13C-labeled metabolic substrates, and the development of a process for delivering them into living subjects, have totally changed the clinical potential of MRS of 13C-labeled metabolic substrates. Preliminary preclinical studies in a model of prostate cancer have demonstrated the potential clinical utility of hyperpolarized 13C MRS.
Key Words: molecular imaging MRI 13C magnetic resonance spectroscopy
FOOTNOTES
COPYRIGHT © 2008 by the Society of Nuclear Medicine, Inc.
Related articles in JNM:
This article has been cited by other articles:
![]() |
W. S. Warren, E. Jenista, R. T. Branca, and X. Chen Increasing Hyperpolarized Spin Lifetimes Through True Singlet Eigenstates Science, March 27, 2009; 323(5922): 1711 - 1714. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |